Gainers:
Whirlpool Corp. (WHR) is gaining nearly 9 percent to $59.11. The company's fourth quarter profit increased 20 percent from the year-ago quarter. Meanwhile, the company issued an above-consensus earnings guidance for 2012.
Morgan Stanley (MS) is up over 2 percent to $19.10 amidst reports that Facebook has selected the company as the lead bookrunner for its highly anticipated initial public offering.
Sangamo BioSciences, Inc. (SGMO) is rising nearly 9 percent to $3.75. The company has entered into a collaboration and license agreement with Shire plc (SHP.L, SHPGY) to develop therapeutics for hemophilia and other monogenic diseases based on its zinc finger DNA-binding protein technology. Shire will pay Sangamo $13 million upfront followed by research, regulatory, development and commercial milestone payments, and royalties on product sales.
Seagate Technology. (STX) is up 9 percent to $23.10 as its second quarter profit and revenue surged from the previous year period. Both earnings and revenues were above consensus.
Medivation, Inc. (MDVN) is jumping 19 percent to $66.00. The company reported positive results on all efficacy endpoints from the Phase 3 AFFIRM trial of the investigational drug MDV3100 in men with prostate cancer previously treated with chemotherapy.
Decliners:
Amazon.com, Inc. (AMZN) is falling over 9 percent to $176.10 as the company's fourth quarter profit declined from the year-ago quarter. Earnings per share were above Wall Street view. Net sales increased 35 percent, but were below consensus. The company provided a weak sales forecast for the first quarter and warned of a potential operating loss in the quarter.
Georgia Gulf Corp. (GGC) is falling more than 5 percent to $33.10 based on the news that it has rejected a revised proposal of $35 per share from Westlake Chemical Corp. (WLK). Westlake said it has decided that it will not nominate director candidates for Georgia Gulf's 2012 annual meeting of stockholders.
Trading halt:
Trading in shares of Impax Laboratories, Inc. (IPXL) was halted. The company has licensed from AstraZeneca the exclusive U.S. commercial rights to Zomig tablet, orally disintegrating tablet, and nasal spray formulations. The company will pay AstraZeneca quarterly payments totaling $130 million during 2012, and thereafter, tiered royalties on future sales of zolmitriptan products. The company expects this transaction to be immediately accretive on a non-GAAP basis to its earnings per share in 2012.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.